BlackRock, Inc. Reduces Stake in Coherus Oncology, Inc. to 4.9%

BlackRock, Inc. filed a Schedule 13G/A (Amendment No. 6) on April 27, 2026, regarding its holdings in Coherus Oncology, Inc. (CHRS). As of the event date on March 31, 2026, BlackRock reported beneficial ownership of 7,337,261 shares of common stock, representing a 4.9% stake in the company. This filing marks a decrease in ownership to below the 5% threshold, as the previous reported position was above this level. Of the total shares held, BlackRock has sole voting power over 7,232,734 shares and sole dispositive power over all 7,337,261 shares. The filing indicates that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Various subsidiaries of BlackRock, Inc. are listed as having acquired the shares, but no single person's interest exceeds five percent of the total outstanding common shares. The filing was executed by Spencer Fleming, Managing Director, and confirms the filer's status as a parent holding company.